Opinion
Abuse of the Safety-Net 340B Drug Pricing Program: Why Should Physicians Care?
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: November 18, 2024
Opinion

‘Reform School’ for Pharmacy Benefit Managers: How Might Legislation Help Patients?
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: September 17, 2024
News

Fed Worker Health Plans Ban Maximizers and Copay Accumulators: Why Not for the Rest of the US?
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: July 29, 2024
Opinion

Specialists Are ‘Underwater’ With Some Insurance-Preferred Biosimilars
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: May 16, 2024
Opinion

ERISA Health Plan Lawsuits: Why Should We Care?
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: March 15, 2024
Opinion

Biosimilar Business Deals Keep Up ‘Musical Chairs’ Game of Formulary Construction
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: January 17, 2024
News

Prescription drug affordability boards: Another quick fix with unintended consequences?
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: November 17, 2023
News

Insurer’s foray into AI-based ‘shared savings’ program creates ethical problems
- Author:
- Madelaine (Mattie) A. Feldman, MD
Publish date: September 20, 2023